BioElectronic launches migraine study for ActiPatch pulsed shortwave therapy

Non-invasive electroceutical developer BioElectronics said today it launched a clinical study of its ActiPatch, examining the use of the device for treating migraines.

The ActiPatch is a series of patches or wraps which use electromagnetic pulse therapy to treat chronic pain, according to the Frederick, Md.-based company’s website.

In the randomized, double-blinded placebo controlled study, investigators aim to examine the efficacy of the ActiPatch in preventing chronic migraine attacks.

A total of 48 patients are slated to be enrolled in the trial, which will take place in 2, 4-week periods, with the 1st serving as a run-in period with no therapy and a treatment or placebo period for the rest of the subjects.

“Migraine is the fastest growing category in the chronic pain market, but existing therapies work poorly. A successful study will help in seeking a non-prescription indication for the prevention of migraines, from the FDA,” product dev VP Sree Koneru said in a press release.

The post BioElectronic launches migraine study for ActiPatch pulsed shortwave therapy appeared first on MassDevice.

from MassDevice http://ift.tt/2sj6i09